The aim of our study was to answer these unresolved questions by investigating PRAME expression in thin melanomas (≤1.00 mm) and SDN including ambiguous melanocytic tumors with long-term follow-up in a real-world setting. The gene discussed is PRAME; the disease is melanoma.